KALA Bio shares rose 57.10% to $0.79 in after-hours trading Tuesday after the clinical-stage biopharmaceutical company announced a non-binding letter of intent to acquire 100% of a privately held management services organization supporting a telehealth platform. The LegitScript-certified and NABP-accredited platform serves clients in all 50 states and generated approximately $12.7 million in unaudited revenue during the trailing 12 months ended August 2026. The proposed acquisition is valued at approximately $15 million, payable in cash and KALA stock, with the cash portion funded from existing balance-sheet resources. Founded in 2023, the target has served more than 90,000 clients and generated over $48 million in sales across GLP-1 weight management, hormone health, longevity and sexual wellness. KALA expects a 45-day due diligence process to conclude in November 2026 and is targeting a closing in late 2026 or early 2027. KALA shares have fallen 99.34% over the past year and have traded between $123.00 and $0.40.